004720.KS
PharmGen Science, Inc.
KSC · Healthcare · Drug Manufacturers - General · KR
KRW 3,140.00
−0.63%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 175.4B | 173.1B | 171.3B | 166.8B | 150.9B |
| Cost of Revenue | 62.7B | 63.9B | 63.3B | 70.6B | 69.6B |
| Gross Profit | 112.7B | 109.1B | 108.0B | 96.2B | 81.3B |
| Operating Expenses | |||||
| R&D Expense | 7.3B | 4.6B | 4.4B | 5.1B | 2.9B |
| SG&A Expense | 89.5B | 81.6B | 71.4B | 81.6B | 47.8B |
| General & Admin Expense | 8.7B | 11.5B | 8.6B | 7.5B | 7.2B |
| Selling & Marketing Expense | 53.9B | 70.2B | 62.9B | 54.4B | 40.6B |
| Other Expenses | 13.2B | 16.9B | 21.5B | 327.0M | 23.1B |
| Total Operating Expenses | 108.8B | 103.2B | 97.4B | 87.1B | 73.8B |
| Cost and Expenses | 171.5B | 167.1B | 160.6B | 157.7B | 143.4B |
| Operating Income (EBIT) | 3.9B | 6.0B | 10.6B | 9.1B | 9.3B |
| Non-Operating | |||||
| Interest Income | 568.6M | 49.7M | 100.0M | 98.4M | 66.0M |
| Interest Expense | 434.7M | 1.4B | 4.2B | 4.3B | 3.5B |
| Net Interest Income | 133.9M | (1.3B) | (4.1B) | (4.2B) | (3.4B) |
| Other Non-Op Income/Expense | (173.5B) | (157.1B) | (9.6B) | (1.1B) | 82.5B |
| Non-Operating Income (excl Interest) | — | — | 5.5B | (3.6B) | 1.9B |
| EBT (Pre-Tax Income) | (169.6B) | (151.1B) | 1.0B | 8.0B | 90.0B |
| Income Tax Expense | (35.2B) | (34.5B) | (1.8B) | 2.3B | 19.9B |
| Bottom Line | |||||
| Net Income | (134.4B) | (116.6B) | 2.8B | 5.7B | 70.1B |
| Earnings from Cont. Ops | (134.4B) | (116.6B) | 2.8B | 6.1B | 70.1B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (134.3B) | (116.6B) | 2.8B | 5.7B | 70.1B |
| Per Share | |||||
| Basic EPS | (₩6,137) | (₩5,313) | ₩154 | ₩374 | ₩4,498 |
| Diluted EPS | (₩6,137) | (₩5,313) | ₩152 | ₩324 | ₩3,369 |
| Revenue Per Share | ₩7,927 | ₩7,883 | ₩9,445 | ₩10,244 | ₩9,691 |
| Shares | |||||
| Basic Shares Outstanding | 22.1M | 22.0M | 18.1M | 16.3M | 15.6M |
| Diluted Shares Outstanding | 22.1M | 22.0M | 21.8M | 20.8M | 21.6M |
| Profitability Metrics | |||||
| EBITDA | 8.6B | 10.5B | 10.8B | 13.4B | 10.8B |
| D&A | 4.7B | 4.6B | 4.6B | 4.2B | 3.4B |
| EBIT | 3.9B | 6.0B | 6.2B | 9.1B | 7.4B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026